Manisha Mone
Novartis
25 Papers
524 Citations
Manisha Mone is an academic researcher from Novartis. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 19, co-authored 25 publications.
Chat about Author
Papers
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib
Michael W. Deininger,Stephen G. O'Brien,François Guilhot,John M. Goldman,Andreas Hochhaus,Timothy P. Hughes,Jerald P. Radich,Alan Hatfield,Manisha Mone,Jeiry Filian,John V. Reynolds,Insa Gathmann,Richard A. Larson,Brian J. Druker +13 more
TL;DR: CML-CP pts responding to IM had a low overall risk of progression to AP/BC and the safety profile of IM remains unchanged after 8 yr, with no previously unreported AEs identified over the past 36 mo.
705
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Karl D. Lewis,Patrick Combemale,R. Herd,Ragini R. Kudchadkar,Uwe Trefzer,Sven Gogov,Celine Pallaud,Tingting Yi,Manisha Mone,Martin Kaatz,Carmen Loquai,Alexander J. Stratigos,Hans Joachim Schulze,Ruth Plummer,Anne Lynn S. Chang,Frank Cornelis,John T. Lear,Dalila Sellami,Reinhard Dummer +22 more
TL;DR: The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.
387
1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Edwin Bernard Villhauer,John A Brinkman,Goli B Naderi,Beth E. Dunning,Bonnie L Mangold,Manisha Mone,Mary E Russell,Stephen Craig Weldon,Thomas Edward Hughes +8 more
TL;DR: One compound, NVP-DPP728, is profiled as a potent, selective, and short-acting DPP-IV inhibitor that has excellent oral bioavailability and potent antihyperglycemic activity.
180
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
John T. Lear,Michael R. Migden,Karl D. Lewis,Anne Lynn S. Chang,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Patrick Combemale,Alexandros Stratigos,Ruth Plummer,Henry Castro,Tingting Yi,Manisha Mone,Jocelyn Zhou,Uwe Trefzer,Martin Kaatz,Carmen Loquai,Ragini R. Kudchadkar,Dalila Sellami,Reinhard Dummer +19 more
TL;DR: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options.
175
NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.
Thomas Edward Hughes,Manisha Mone,Mary E Russell,Stephen Craig Weldon,Edwin Bernard Villhauer +4 more
TL;DR: The data suggest that NVP-DPP728 inhibits DPP-IV through formation of a novel, reversible, nitrile-dependent complex with transition state characteristics, which is consistent with a two-step inhibition mechanism.
166